Analysis of the epidemiological characteristics of multiple myeloma and clinical factors affecting the course of the disease
https://doi.org/10.58708/2074-2088.2023-1(29)-55-61
Abstract
Multiple myeloma (MM) is the second most common malignant neoplasm of the hematopoietic system. Survival rate has improved significantly in patients over the past decade with the use of new therapeutic strategies. The absence of adverse factors at the time of diagnosis does not always determine a positive course of the disease. Therefore, the search for prognostic factors is relevant. The article presents data based on the epidemiological characteristics and clinical factors of MM that affected the progression-free survival. We have shown that a significant excess of the levels of IL2, IL6, TNF, the level of clonal CD138+ >20% at the time of diagnosis is associated with an increase in the frequency of disease progression.
A decrease in progression-free survival was detected at kidney damage, anemic syndrome, infectious complications, multiple skeletal bone lesions, genetic changes at the time of diagnosis and did not depend on the type of immunoglobulin secretion.
About the Authors
Zh. M. Kozich
ГУ «РНПЦ радиационной медицины и экологии человека»
Belarus
Belarus
V. N. Martinkov
ГУ «РНПЦ радиационной медицины и экологии человека»
Belarus
Belarus
I. V. Veyalkin
ГУ «РНПЦ радиационной медицины и экологии человека»
Belarus
Belarus
J. N. Pugacheva
ГУ «РНПЦ радиационной медицины и экологии человека»
Belarus
Belarus
D. A. Blizin
ГУ «РНПЦ радиационной медицины и экологии человека»
Belarus
Belarus
N. N. Klimkovich
УО «Белорусская медицинская академия последипломного образования»
Belarus
Belarus
References
1. Palumbo, A. Multiple myeloma / A. Palumbo, K. Anderson // N. Engl. J. Med. – 2011. – Vol. 364, №11. – P. 1046-1060.
2. Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma / G.P. Kaufman [и др.] // Leukemia. – 2016. – Т. 30, №3. – С. 633-639.
3. Rajkumar, S.V. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management / S.V. Rajkumar // Am. J. Hematol. – 2022. – Vol. 97, №8. – P. 1086-1107.
4. Corre, J. Risk factors in multiple myeloma: is it time for a revision? / J. Corre, N.C. Munshi, H. AvetLoiseau // Blood. – 2021. – Vol. 137, №1. – P. 16-19.
5. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project / M. D’Agostino [et al.] // J. Clin. Oncol. – 2022. – Vol. 40, № 29. – P. 3406-3418.
6. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma / S.V. Rajkumar [et al.] // Lancet. Oncol. – 2014. – Vol. 15, №12. – P. e538–e548.
7. Метод комплексного лечения пациентов с множественной миеломой на основе применения высокодозной химиотерапии в сочетании с трансплантацией гемопоэтических стволовых клеток на различных этапах консолидации: инструкция по применению: утв. МЗ РБ 28.12.2018 г. / А.Л. Усс [и др.]. – Минск: ГУ«Минский научно-практический центр хирургии, трансплантологии и гематологии», 2018. – 12 с.
8. Podar, K. Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond / K. Podar, X. Leleu // Cancers (Basel). – 2021. – Vol. 13, №20. – P. 5154.
9. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. / P. Moreau [et al.] // Blood. – 2002. – Vol. 100, №5. – P. 1579-1583.
10. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups / N. Bolli [et al.] // Leukemia. – 2018. – Vol. 32, №12. – P. 2604-2616.
11. Cytokine-Mediated Dysregulation of Signaling Pathways in the Pathogenesis of Multiple Myeloma / S. Akhtar [et al.] // Int. J. Mol. Sci. – 2020. – Vol. 21, №14. – P. 5002.
12. Bone disease in multiple myeloma: pathophysiology and management / A. Hameed [et al.] // Cancer Growth Metastasis. – 2014. – Vol. 7. – P. 33-42.
13. Ludwig, H. Anemia in multiple myeloma / H. Ludwig, G. Pohl, A. Osterborg // Clin. Adv. Hematol. Oncol. – 2004. – Vol. 2, №4. – P. 233-241.
14. Эффективность и безопасность аутологичной трансплантации некриоконсервированных гемопоэтических стволовых клеток у больных множественной миеломой / С.В. Волошин [и др.] // Онкогематология. – 2022. – Т. 17, №2. – С. 82-94.
Review
For citations:
Kozich Zh.M., Martinkov V.N., Veyalkin I.V., Pugacheva J.N., Blizin D.A., Klimkovich N.N. Analysis of the epidemiological characteristics of multiple myeloma and clinical factors affecting the course of the disease. Medical and Biological Problems of Life Activity. 2023;(1):55-61. (In Russ.) https://doi.org/10.58708/2074-2088.2023-1(29)-55-61
Views: 230
Email this article 